VXRT:OTCMKTS
Vaxart Inc
0,43Â US$
arrow_downward
-0,02%(-0,000075) 1K
9-okt, 16:00:00 (GMT-4) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoVXRT tikeri uchun statistika yaratilmoqda...
Ochish
0,44Â US$
Yuqori
0,45Â US$
Past
0,43Â US$
Bozor kapitali
106,59Â mln
Oʻrtacha hajm
265,13Â ming
Hajmi
198,22Â ming
P/E koeffitsiyenti
2,66
52 haftalik eng yuqori
0,84Â US$
52 haftalik eng past
0,30Â US$
Aksiya boʻyicha daromad
0,16Â US$
Beta
1,05
Muomaladagi aksiyalar
242,84Â mln
Xodimlar soni
65
Ochish
0,44Â US$
Yuqori
0,45Â US$
Past
0,43Â US$
Bozor kapitali
106,59Â mln
Oʻrtacha hajm
265,13Â ming
Hajmi
198,22Â ming
P/E koeffitsiyenti
2,66
52 haftalik eng yuqori
0,84Â US$
52 haftalik eng past
0,30Â US$
Aksiya boʻyicha daromad
0,16Â US$
Beta
1,05
Muomaladagi aksiyalar
242,84Â mln
Xodimlar soni
65
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Simply Wall Street
·
38 daqiqa oldin
EBay (EBAY) Tightens Seller Rules In Australia And The US
MarketBeat
·
28 daqiqa oldin
Quantum-Si (NASDAQ:QSI) Stock Rating Raised to "Hold" at Wall Street Zen
MarketBeat
·
28 daqiqa oldin
Rush Enterprises (NASDAQ:RUSHA) Rating Lowered to Hold at Wall Street Zen
Yahoo Finance
·
7 soat oldin
A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year
Profil
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
Vaxart Inc haqida
CEO-
Xodimlar soni65
Asos solinganmar 2004
Bosh ofislarSouth San Francisco, Kaliforniya, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytvaxart.com